Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Recombinant Human Thymosin Beta 4 in Healthy Volunteers
NCT04555824Phase 1Completed
- Sponsor
- Northland Biotech
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of thymosin beta-4 in acute myocardial infarction (AMI) (8 arms), sponsored by Northland Biotech. Primary endpoints: Maximum Tolerated Dose at Day 1, Number of participants with treatment-related adverse events at Day 1 and 9 more. Started Jul 2017; status: completed.
02
Drugs
thymosin beta-4
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT04555824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555824.